The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.
 
Omid Hamid
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Immunocore (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Rinat (Inst); Roche (Inst)
 
Todd Michael Bauer
Employment - Sarah Cannon Research Institute; Tennessee Oncology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunogen (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Principa Biopharma (Inst); Stemline Therapeutics (Inst)
 
Alexander I. Spira
Honoraria - ARIAD; Clovis Oncology; Novartis; Roche
Consulting or Advisory Role - ARIAD; Clovis Oncology; Roche/Genentech
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Ignyta (Inst); Incyte (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - ARIAD; Clovis Oncology; Roche
 
David C. Smith
Research Funding - Agensys (Inst); Atterocor (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); ESSA (Inst); Exelixis (Inst); Genentech (Inst); ImClone Systems (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Medivation/Astellas (Inst); Millennium (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Regeneron (Inst); Seagen (Inst); Takeda (Inst); Tekmira (Inst); Teva (Inst)
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; G1 Therapeutics; Kyowa Hakko Kirin; Merck; Takeda
Research Funding - Advaxis (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ignyta (Inst); Immunocore (Inst); Incyte (Inst); Kura Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Churchill Pharmaceuticals; G1 Therapeutics; Kyowa Hakko Kirin; Takeda
 
Ahmad A. Tarhini
Consulting or Advisory Role - Bristol-Myers Squibb; Merck
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Prometheus (Inst)
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Exelixis; Genentech/Roche; Halozyme; Janssen; Novartis; PER; Pfizer; Sanofi; Turnstone Bio
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Polaris (Inst); TRACON Pharma (Inst)
 
Thomas Gajewski
Consulting or Advisory Role - Abbvie; Aduro Biotech; Amgen; Bayer; FORMA Therapeutics; Jounce Therapeutics; Merck; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Licensing to Evelo (Inst)
 
Jeffrey S. Wasser
Stock and Other Ownership Interests - Biogen; Bristol-Myers Squibb; Johnson & Johnson; Lilly; Merck (I); Pfizer (I)
Consulting or Advisory Role - Amgen; Novartis
Research Funding - Amgen; Incyte; Pfizer
Travel, Accommodations, Expenses - Amgen
 
Sandip P. Patel
Consulting or Advisory Role - Lilly; Novartis
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - Bristol-Myers Squibb; Incyte; Lilly; MedImmune; Pfizer; Roche/Genentech; Xcovery
 
Virginia F. Borges
Research Funding - Abbott/AbbVie (Inst); Advaxis (Inst); Galena Biopharma (Inst); Incyte (Inst); Merrimack (Inst); Oncothyreon (Inst)
 
Ani Sarkis Balmanoukian
Speakers' Bureau - Bristol-Myers Squibb; Genentech; Merck
Research Funding - Genentech; Incyte; MedImmune; Merck; Merck Serono
 
Emmett V. Schmidt
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yufan Zhao
Employment - Amgen (I); Incyte
Stock and Other Ownership Interests - Amgen (I); Incyte
Travel, Accommodations, Expenses - Amgen (I); Incyte
 
Mark M. Jones
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Tara C. Gangadhar
Honoraria - Medscape
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst)